title: [Experience of application of pneumococcus vaccines for studies of humoral immunity].
abstract: OBJECTIVE
  Evaluate possible use of Pneumo-23 pneumococcus polysaccharide vaccine and Prevenar-7 conjugated vaccine in EIA as antigens for determination of IgG levels against capsule polysaccharides.
  
  
  METHODS
  Solid phase EIA method with sorption on polystyrol of commercial vaccines Penumo-23 and Prevenar-7 was used in the study. Blood sera of 41 children before immunization and sera of 8 children before and after vaccination with Pneumo-23 and Prevenar-7 were analyzed. IgG level was determined in standard units (u.).
  
  
  RESULTS
  Mean level of antibodies in groups of unimmunized children against antigens of both vaccines were in the range of 52.3-69.1 u. (p > 0.05). The number of children with diagnostically significant level of antibodies (114 - 120 u.) was 2.4% in the control group (1/41) when Pneumo-23 antigens were used and 7.3% (3/41) when Prevenar-7 antigens were used. After vaccination with Pneumo-23 the fraction of diagnostically significant level of antibodies against Pneumo-23 antigens was on average higher by 1.8 times than in pre-vaccination period in 62.5% of children, and against Prevenar-7 antigens - by 1.6 times higher in 75% of children. After immunization with Prevenar-7 vaccine the level of antibodies increased by 3-4 times against antigens of both vaccines and reached diagnostically significant in 100% of cases.
  
  
  CONCLUSIONS
  Pneumo-23 and Prevenar-7 pneumococcal vaccines may be used as antigens for determination of antibodies against capsule polysaccharides of Streptococcus pneumoniae in EIA. Higher sensitivity of EIA based on Prevenar-7 allows to recommend this test for studies of postvaccination immunity in immunized with both conjugated and non-conjugated polysaccharide pneumococcal vaccines.
authors.forename: N E
authors.initials: NE
authors.lastname: Iastrebova
authors.forename: N V
authors.initials: NV
authors.lastname: Grishchenko
authors.forename: M P
authors.initials: MP
authors.lastname: Kostinov
authors.forename: O A
authors.initials: OA
authors.lastname: Salkina
authors.forename: N V
authors.initials: NV
authors.lastname: Snegova
authors.forename: N P
authors.initials: NP
authors.lastname: Vaneeva
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood* / Q000276:immunology; D000918:Antibody Specificity; D016667:Bacterial Capsules / Q000276:immunology; D002675:Child, Preschool; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D056724:Immunity, Humoral / Q000187:drug effects*; D007074:Immunoglobulin G / Q000097:blood* / Q000276:immunology; D007223:Infant; D008297:Male; D011008:Pneumococcal Infections / Q000097:blood* / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology; D013296:Streptococcus pneumoniae / Q000276:immunology; D014611:Vaccination
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; D000907:Antibodies, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial